Trimodality management of malignant pleural mesothelioma

被引:61
|
作者
Maggi, G [1 ]
Casadio, C [1 ]
Cianci, R [1 ]
Rena, O [1 ]
Ruffini, E [1 ]
机构
[1] Univ Turin, San Giovanni Battista Hosp, Dept Thorac Surg, I-10126 Turin, Italy
关键词
malignant pleural mesothelioma; pleural disease; extrapleural pneumonectomy; pleurectomy/decortication;
D O I
10.1016/S1010-7940(01)00594-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM). Methods: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy. Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD). Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded. Results. Our series included 21 men and 11 women with a median age of 53.5 years (range 40-69). Histologically, there were 26 epithelial, four mixed and two sarcomatous MPM. Post-surgical staging was as follows: six patients were at Stage I; of these, two received a P/D and four a PPPD. Ten patients were at Stage Il and all received a PPPD; 16 patients were at Stage m (under-staged pre-operatively): of these, nine patients presented extrapleural lymph node metastases (N2) and all received a PPPD, seven patients presented with chest wall or mediastinal invasion (T4) with macroscopic residual tumour, and ail received a de-bulking P/D. We observed major complications in ten patients: six bleeding, two respiratory insufficiency and two nerve paralysis. There were two perioperative deaths (6.25% mortality). Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months. Conclusions: (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:346 / 350
页数:5
相关论文
共 50 条
  • [1] TRIMODALITY TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
    Sottero, T.
    Kusano, A.
    Truong, A.
    Laramore, G.
    Stelzer, K.
    Patel, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (01) : 228 - 228
  • [2] Trimodality treatment of malignant pleural mesothelioma
    Batirel, Hasan Fevzi
    Metintas, Muzaffer
    Caglar, Hale Basak
    Yildizeli, Bedrettin
    Lacin, Tunc
    Bostanci, Korkut
    Akgul, Asli Gul
    Evman, Serdar
    Yuksel, Mustafa
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (05) : 499 - 504
  • [3] Trimodality Therapy for Malignant Pleural Mesothelioma
    Buduhan, Gordon
    Menon, Shekhar
    Aye, Ralph
    Louie, Brian
    Mehta, Vivek
    Vallieres, Eric
    ANNALS OF THORACIC SURGERY, 2009, 88 (03): : 870 - 876
  • [4] Trimodality therapy in the treatment of malignant pleural mesothelioma
    Castagnelo, B
    Manzin, E
    Zai, S
    Casadio, C
    Maggi, G
    Rovea, P
    Ozzello, F
    Botta, M
    Brelli, S
    ANNALS OF ONCOLOGY, 2000, 11 : 2 - 2
  • [5] Trimodality management of malignant pleural mesothelioma - Appendix A. Conference discussion
    Sokolov, VV
    Maggi
    Thorpe, J
    Baptista, P
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 19 (03) : 350 - 350
  • [6] The Role of Radiation and Trimodality Treatment for Malignant Pleural Mesothelioma
    Sottero, T. L.
    Kusano, A. S.
    Laramore, G. E.
    Stelzer, K. J.
    Martins, R. G.
    Patel, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S509 - S509
  • [7] Management of malignant pleural mesothelioma in the era of trimodality therapy: solved and unsolved questions
    Marulli, Giuseppe
    Zuin, Andrea
    Schiavon, Marco
    Nicotra, Samuele
    Favaretto, Adolfo G.
    Loreggian, Lucio
    Sartori, Francesco
    Rea, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S780 - S781
  • [8] Trimodality Treatment of Malignant Pleural Mesothelioma An Institutional Review
    Kapeles, Matthew
    Gensheimer, Michael F.
    Mart, Dylan A.
    Sottero, Theo L.
    Kusano, Aaron S.
    Anh Truong
    Farjah, Farhood
    Laramore, George E.
    Stelzer, Keith J.
    Patel, Shilpen A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 30 - 35
  • [9] The Results of Trimodality Treatment Strategy for Malignant Pleural Mesothelioma
    Okabe, K.
    Tao, H.
    Hayashi, M.
    Furukawa, M.
    Miyazaki, R.
    Murakami, D.
    Hara, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2307 - S2308
  • [10] Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
    Ozyurt, Hazan
    Ozdemir, Sevim
    Dogan, Bedriye
    Gunalp, Gun
    Ozden, Ayse Sevgi
    NORTHERN CLINICS OF ISTANBUL, 2023, 10 (02) : 172 - 180